Shire's ADHD med Vyvanse holds off binge eating in trial for new indication

Shire ($SHPG) shares spiked to an all-time high after the company revealed new data showing its ADHD drug Vyvanse was effective at treating binge eating disorder. The company plans to ask the FDA next year to approve the new indication. Binge eating was newly recognized as an official disorder in the latest Diagnostic and Statistical Manual, which guides psychiatric treatment. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.